JP Morgan Chase
CLPT icon

JP Morgan Chase’s ClearPoint Neuro CLPT Stock Holding History

JP Morgan Chase’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311K Sell
15,988
-71
-0.4% -$887 ﹤0.01% 5375
2026
Q1 		$139K Buy
16,059
+2,128
+15% +$26.9K ﹤0.01% 5660
2025
Q4 		$191K Sell
13,931
-29,027
-68% -$538K ﹤0.01% 5570
2025
Q3 		$936K Buy
42,958
+10,168
+31% +$120K ﹤0.01% 4644
2025
Q2 		$392K Buy
32,790
+8,581
+35% +$108K ﹤0.01% 4903
2025
Q1 		$288K Buy
24,209
+23,661
+4,318% +$368K ﹤0.01% 5079
2024
Q4 		$8.43K Sell
548
-9,222
-94% -$119K ﹤0.01% 6420
2024
Q3 		$110K Buy
9,770
+3,612
+59% +$34.6K ﹤0.01% 5658
2024
Q2 		$33.2K Sell
6,158
-9,694
-61% -$56.1K ﹤0.01% 6004
2024
Q1 		$108K Sell
15,852
-15,570
-50% -$109K ﹤0.01% 5639
2023
Q4 		$213K Sell
31,422
-10,382
-25% -$58.8K ﹤0.01% 5359
2023
Q3 		$209K Sell
41,804
-8,770
-17% -$52.2K ﹤0.01% 5045
2023
Q2 		$366K Buy
50,574
+14,356
+40% +$122K ﹤0.01% 4682
2023
Q1 		$306K Buy
36,218
+1,719
+5% +$15.1K ﹤0.01% 4796
2022
Q4 		$292K Buy
34,499
+1,693
+5% +$16K ﹤0.01% 4836
2022
Q3 		$340K Sell
32,806
-698
-2% -$9.2K ﹤0.01% 4680
2022
Q2 		$437K Sell
33,504
-23,855
-42% -$244K ﹤0.01% 4648
2022
Q1 		$597K Buy
57,359
+4,726
+9% +$43K ﹤0.01% 4593
2021
Q4 		$590K Buy
52,633
+1,413
+3% +$21.2K ﹤0.01% 4718
2021
Q3 		$910K Sell
51,220
-1,650
-3% -$30.9K ﹤0.01% 4385
2021
Q2 		$1.01M Buy
52,870
+9,050
+21% +$175K ﹤0.01% 4276
2021
Q1 		$926K Buy
43,820
+2,493
+6% +$53.4K ﹤0.01% 4285
2020
Q4 		$657K Buy
41,327
+39,819
+2,641% +$357K ﹤0.01% 4220
2020
Q3 		$9K Hold
1,508
– – ﹤0.01% 5268
2020
Q2 		$5K Buy
1,508
+8
+0.5% +$30 ﹤0.01% 5181
2020
Q1 		$5K Sell
1,500
-1,500
-50% -$7.37K ﹤0.01% 5117
2019
Q4 		$14K Hold
3,000
– – ﹤0.01% 5351
2019
Q3 		$15K Buy
+3,000
New +$12.3K ﹤0.01% 5448

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
CFM
Compass Financial Management Tampa, Florida $829M AUM

JP Morgan Chase's CLPT Position: Q2 2026 in Review

JP Morgan Chase reduced its ClearPoint Neuro (CLPT) stake by 0.44% in Q2 2026, selling an estimated $887 and leaving 15,988 shares worth $311K. The position accounts for ﹤0.01% of the portfolio, ranked #5375.

JP Morgan Chase first reported a position in CLPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.01M in Q2 2021. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • JP Morgan Chase held 15,988 shares of ClearPoint Neuro worth $311K as of Q2 2026.
  • JP Morgan Chase sold 71 ClearPoint Neuro shares in Q2 2026, an estimated $887.
  • ClearPoint Neuro made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5375 holding.
  • JP Morgan Chase first reported a position in ClearPoint Neuro in Q3 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's ClearPoint Neuro position peaked at $1.01M in Q2 2021.
  • 129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.